Anna manages all collaborative projects encompassing cell therapy development, GMP translation, and the manufacture of cell therapies for pre-clinical and clinical development.

Anna has extensive experience in cell culture and most methods in molecular and cell biology. She has a doctorate degree in Cell Biology from the University of Tartu. Her research was focused on cancer-associated molecular mechanisms. The main emphasis was on the signaling pathways which contribute to tumor development through facilitating cell growth and survival. Another important part of her study concerned programmed cell death which was triggered in response to oncogene activation.

At the Tallinn University of Technology, Anna investigated the adhesion and migration of human melanoma cells.

Anna Balikova, PhD

 
PUBLICATIONS

Balikova, A., Jääger, K., Viil, J., Maimets, T. and Kadaja-Saarepuu, L. (2012)

Leukocyte marker CD43 promotes cell growth in co-operation with β-catenin in non-hematopoietic cancer cells. Int J Oncol 41:299-309

 

Kadaja-Saarepuu, L., Lõoke, M., Balikova, A. and Maimets, T. (2011) Tumor suppressor p53 down-regulates expression of human leukocyte marker

CD43 in non-hematopoietic tumor cells. Int J Oncol 40(2):567-76. 

 

Kadaja-Saarepuu, L., Laos, S., Jääger, K., Viil, J., Balikova, A., Lõoke, M.,Hansson, G.C. and Maimets, T. (2008) CD43 promotes cell growth and

helps to evade FAS-mediated apoptosis in non-hematopoietic cancer cells lacking the tumor suppressors p53 or ARF. Oncogene 27(12):1705-15.

CELLIN TECHNOLOGIES
MÄEALUSE 4
TALLINN 12618
ESTONIA
E-mail: info@cellintechnologies.com
Phone: +372 502 2628
IBAN       EE552200221048073425
SWIFT    HABAEE2X 
VAT NR   EE101262352

©2021 by Cellin Technologies